First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn(Vanderbilt University), Stephen V. Liu(Georgetown University), Libor Havel(Chinese University of Hong Kong), Maximilian J. Hochmair(Karl Landsteiner Society), Sivuonthanh Lam(Chinese University of Hong Kong), Florian Huemer(Chinese University of Hong Kong), David S. Shames(Gene Therapy Laboratory), Melissa L. Johnson(Tennessee Oncology), György Losonczy(Chinese University of Hong Kong), Martin Reck(German Center for Lung Research), Tony Mok(Chinese University of Hong Kong), Aaron S. Mansfield(Mayo Clinic), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Beiying Ding(Chinese University of Hong Kong), Makoto Nishio(Japanese Foundation For Cancer Research), Alan Sandler(Chinese University of Hong Kong), Juan Liu(Unknown), Ariel López-Chávez(Chinese University of Hong Kong), Wei Lin(Chinese University of Hong Kong), Aleksandra Szczęsna(Chinese University of Hong Kong), Fairooz F. Kabbinavar(Kaiser Permanente)
Cited by 3,496
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k